Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants

Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants
Conditions: Ovarian Neoplasms; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation; Serous Tubal Intraepithelial Carcinoma; Early Detection of Ovarian Cancer

Interventions: Device: Galleri Multi-Cancer Early Detection (MCED) Blood Test

Sponsors: Weill Medical College of Cornell University; M.D. Anderson Cancer Center

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 15, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments